drugset
drugset / Trial / NCT01884337

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

NCT01884337 ↗

Phase 4 Completed 557 enrolled Bristol-Myers Squibb Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement

Timeline

Start
2015-03-24
Primary completion
2018-06-04
Completion
2018-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg Oral

Indications

No indication recorded.